Targets › PTPN11
3 programs from 3 companies in 4 trials: 3 Phase 1, 1 Phase 3; Oncology; next expected readout Dec 2026.
Acts downstream of various receptor and cytoplasmic protein tyrosine kinases to participate in the signal transduction from the cell surface to the nucleus. Positively regulates MAPK signal transduction pathway. (UniProt, Q06124)
Open in Phaseline: the race on PTPN11, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Allist Pharmaceuticals | JAB-3312 SHP2 inhibitor | PTPN11 | Phase 3 | Advanced Non-squamous Non-small-cell Lung Cancer; KRAS P.G12C | Mar 2027 |
| HUYABIO International | HBI-2376 SHP2 inhibitor | PTPN11 | Phase 1 | Non Small Cell Lung Cancer | Dec 2026 |
| Novartis | Batoprotafib (TNO155) Protein-tyrosine phosphatase 2C inhibitor | PTPN11 | Phase 1 | KRAS G12C Mutant Solid Tumors | Jan 2027 |
Non Small Cell Lung Cancer (1) KRAS G12C Mutant Solid Tumors (1) Advanced Non-squamous Non-small-cell Lung Cancer (1) KRAS P.G12C (1)
small molecule (2), mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.